First-Line Treatment for EGFR-mutated Advanced/Metastatic Non-Small-Cell Lung Cancer: A 47-Year-Old Woman
Misako Nagasaka, MD, PhD discusses a patient case involving a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC and discusses optimizing 1L EGFR-mutant NSCLC care requires balancing efficacy and toxicity in combination therapies. She also reviews MARIPOSA/FLAURA2 data inform sequencing, AE management, resistance testing, and future innovations.
EP. 1: A 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC
February 10th 2025Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient presents to her primary care physician (PCP) with continued dry cough, dyspnea, and weight loss. She has a history of hypertension, previously managed on an ACE inhibitor, but is now on atenolol.
Watch
The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular profile, comorbidities, and performance status. When discussing options with high-risk patients, healthcare professionals typically take a shared decision-making approach, thoroughly explaining both potential benefits and side effect management strategies. These conversations weigh factors like quality-of-life impact, monitoring requirements, and individual patient preferences to arrive at an optimal treatment strategy.
Watch
The panelist discusses how, Healthcare professionals manage distinct toxicities with ami+laz (IRRs, rash) and osi+chemotherapyctx (cytopenias, diarrhea, fatigue). SKIPPirr informs IRR mitigation in ami’s first infusion. Proactive AE strategies include premedication, dose adjustments, supportive care, and monitoring.
Watch
